Overview

The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the research is to see if Upneeq ( oxymetazoline 0.1% ophthalmic solution) has an effect on eyelid position, eye redness, or patient-perceived appearance of the eyes.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Miami
Treatments:
Ophthalmic Solutions
Oxymetazoline
Pharmaceutical Solutions
Phenylephrine
Criteria
Inclusion Criteria:

- Adults age 18 and above able to provide informed consent to participate

- Subject with stable ocular health, defined as no ocular conditions requiring ongoing
topical therapy or recent surgical intervention

Exclusion Criteria:

- Adults unable to consent

- Individuals less than 18 years of age

- Prisoners

- Pregnant women.

- Known contradictions or sensitivities to study medication (oxymetazoline)

- Ocular surgery within the past 3 months or refractive surgery within the past six
months

- Grossly abnormal lid margins, anatomical abnormalities, previous eyelid or orbital
surgery

- Variable ptosis or eyelid position (e.g., myasthenia gravis, thyroid eye disease, or
blepharospasm)

- Any ocular or systemic condition that, in the opinion of the investigator, would
confound study data, interfere with the subject's study participation, or affected the
subject's safety or trial parameters

- Presence of an active ocular infection

- Prior (within 5 days of beginning study treatment) use of eye whiteners (eg,
vasoconstrictors), decongestants, antihistamines (including over the counter and
herbal topical ophthalmic medications), phenylephrine dilating drops, any other
topical ophthalmic agents

- Inability to sit comfortably for 15 - 30 minutes